Familial Hypobetalipoproteinemia as a Frequently Overlooked Factor in Pediatric Fatty Liver Disease - Top-Institutions - MDSpire

Familial Hypobetalipoproteinemia as a Frequently Overlooked Factor in Pediatric Fatty Liver Disease

  • By

  • Nurit Loberman Nachum

  • Eyal Shteyer

  • Hofit Cohen

  • Odelia Chorin

  • Maya Granot

  • Batia Weiss

  • April 22, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Children's Hospital of Philadelphia
    Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Pediatric Hepatology
    • Genetic Metabolic Disorders
    • Lipidology

  • #2

    Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical Center

    Cincinnati, OH

    Key Differentiators

    • Pediatric Hepatology
    • Genetics
    • Metabolic Disorders

  • #3

    Baylor College of Medicine / Texas Children's Hospital
    Baylor College of Medicine / Texas Children's Hospital

    Houston, TX

    Key Differentiators

    • Pediatric Hepatology
    • Genetic Metabolic Diseases
    • Lipidology

  • #4

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Hepatology
    • Genetics
    • Lipidology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Pediatric Hepatology
    • Genetics
    • Metabolic Liver Disease

Original Source(s)

Familial Hypobetalipoproteinemia as a Frequently Overlooked Factor in Pediatric Fatty Liver Disease

  • by Nurit Loberman Nachum, Eyal Shteyer, Hofit Cohen, Odelia Chorin, Maya Granot, Batia Weiss

  • April 22, 2026

Related Content

Editorial: Digital technologies in hepatology: diagnosis, treatment, and epidemiological insights

Beyond the tumor: the role of the gut microbiome in triple-negative breast cancer

Frontline Pharma: Sarah O’Keeffe

Ahead of HPLC 2026, Eli Lilly’s Sarah O’Keeffe reflects on leadership, collaboration, and the analytical advances helping bring increasingly complex medicines to patients